Curated news and analysis on clinical trials, drug approvals, and medical research.
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
Data from the WINGMEN Phase 0 trial of Xentuzumab in prostate cancer is now available on Oxford's Translational Data Platform, which holds data from over 1,100 participants across five studies.
Novo Nordisk and AWS announced a strategic AI partnership for drug discovery, including a London co-innovation hub. AWS is now the preferred cloud provider, with productivity gains for 25,000 employees.
Nearly 58% of pharmaceutical launches miss expectations, and Deloitte attributes 57% of failures to limited market access. A study of 340 launches shows that organizational commitment architecture, not product superiority alone, drives success. Specialty therapies and exclusivity losses add further pressure.
Flow-based human tissue models show stronger T-cell activity than static cultures, with blinatumomab inducing significant B-cell killing and cytokine release. Sartorius has introduced a 96-well multi-organ tox plate for drug toxicity testing, while in vitro systems are increasingly used as new approach methodologies to complement animal models.
Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
Thermo Fisher posted 10% revenue growth in Q2 and raised guidance; Danaher's Q1 revenue missed but EPS beat. Danaher cited bioprocessing and life sciences strength and expects growth to accelerate.
Rajasthan High Court ruled an expiry date is an opinion, not proof of decomposition. Expired life-saving medicines worth lakhs found at Patahi CHC in Bihar, indicating potential negligence.
Mulago launched a 20-month project to screen Ugandan children for Inborn Errors of Immunity. Studies found 901 variants in uncharacterized genes and 815 variants in humoral IEI genes in Africa.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Revvity beat Q2 expectations, raised its full-year outlook, and launched new drug discovery platforms at SLAS2026. Revenue totaled $711 million with 3% organic growth.
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
Novartis marks 30 years since its 1996 merger, citing advances in targeted therapy, cell therapy, gene therapy, and malaria. It also named a Levant Country President and won two clinical research awards in Saudi Arabia.
AstraZeneca posted Q1 2026 revenue of $15.29B and reported positive sonesitatug vedotin Phase III results, Ultomiris FDA priority review, and Enhertu approval. EMERALD-3 met its PFS endpoint in liver cancer.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Clinical trials show a pancreatic cancer drug nearly doubles survival, a head-and-neck therapy shrinks tumors, and new research explains drug resistance. Cancer mortality is falling in the US and UK.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
FDA issued EUAs for Dectomax and CLiK Extra against New World screwworm. Dectomax is for prevention/treatment in dairy cattle, swine, horses, sheep, deer. CLiK Extra prevents myiasis in livestock, camelids, wildlife.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
